Targeted therapy for breast cancer has focused on receptor tyrosine kinases of the epidermal growth factor receptor (EGFR and ErbB) family, which provide critical checkpoints of cell fate decisions [1,2]. This evidence concerns the gene EGFR and breast carcinoma.